Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, looks to the future of myelofibrosis treatment and discusses ongoing research and the evolving therapeutic landscape.

Addressing financial toxicity associated with myelofibrosis treatment, Dr Mahmoudjafari discusses cost considerations and how lower WAC products can benefit patients.

Dr Mahmoudjafari shares clinical strategies for optimizing patient outcomes and reducing the rate of adverse events and treatment discontinuations.

A clinical pharmacy manager provides insights on optimal patient monitoring practices for patients receiving treatment for myelofibrosis.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, outlines factors that inform treatment decisions for patients with myelofibrosis, including comorbidities and platelet count.

Dr Mahmoudjafari provides an overview of JAK inhibitors available for the treatment of patients with myelofibrosis.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, shares expert perspectives on the important role of risk stratification in determining optimal treatment decisions for patients with low-risk or high-risk myelofibrosis.

An expert on myelofibrosis provides clinical insights on features of the disease that can impact patient quality of life, including splenomegaly, hypertension, and bone pain.

A clinical pharmacy manager discusses challenges frequently encountered in the treatment of patients with myelofibrosis.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, provides an overview of myelofibrosis, covering its incidence and prevalence in the United States as well as patient presentation and prognosis.